Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). - Wikidata - awgldk - TriplyDB

Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

http://www.wikidata.org/entity/Q36666731

about

Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized contro Benefits and harms of citrate locking solutions for hemodialysis catheters: a systematic review and meta-analysis Microbial inactivation properties of a new antimicrobial/antithrombotic catheter lock solution (citrate/methylene blue/parabens).Hemodialysis Tunneled Catheter Noninfectious Complications.Trisodium citrate: an alternative to unfractionated heparin for hemodialysis catheter dwells.Catheter dysfunction: the role of lock solutions.Vascular access in therapeutic apheresis: update 2013.Use of tissue plasminogen activator in catheters used for extracorporeal renal replacement therapy.Urokinase-containing locking solution in the prevention of dialysis catheter dysfunction: a double blind randomized controlled trial.Comparative effectiveness of 30 % trisodium citrate and heparin lock solution in preventing infection and dysfunction of hemodialysis catheters: a randomized controlled trial (CITRIM trial).Anticoagulant therapies versus heparin for the prevention of hemodialysis catheter-related complications: systematic review and meta-analysis of prospective randomized controlled trials.RETRACTED ARTICLE: Anticoagulant agents for the prevention of hemodialysis catheter-related complications: systematic review and meta-analysis of prospective randomized controlled trials.Does antimicrobial lock solution reduce catheter-related infections in hemodialysis patients with central venous catheters? A Bayesian network meta-analysis.Minimizing hemodialysis catheter dysfunction: an ounce of prevention.Acid-citrate-dextrose Formula A versus heparin as primary catheter lock solutions for therapeutic apheresis.Catheter outcomes in the short-term inpatient setting: a controlled quality improvement study comparing citrate and heparin lock.Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis.Chronic Hemodialysis in Small Children.

P2860

Q24185924-71AA1187-BCEF-40F9-8FCD-260627407EC0 Q24193149-101DC1F2-3EE9-482C-AA6D-42C009135E90 Q34895169-4A2CEE69-95A9-45A0-B4E9-C5F419E71E14 Q35551393-4DA38907-96DD-4D8E-8F4A-EE59737ED3A8 Q37198684-1C4D9CD9-D673-4D20-B0EA-F566E29790A7 Q37674559-EC77F473-16A3-40B6-AAE6-8261E1651327 Q37802887-A99FF440-D69E-48D6-B282-BAC5DA769632 Q37969142-C705EB46-70E6-450B-9502-B8600E4F16F3 Q38082736-FB9B4744-A5F6-44CF-858E-3F44BB01632C Q38179478-55248EAC-FF23-4D4F-A6FB-50C920E2104D Q38375466-FEE5D8DC-D8F0-4BAA-A721-D74BF19279DD Q38385564-03AFC255-43C1-4A09-82D0-32DAE59614C5 Q38628552-F6D8F276-DBD7-4AD9-9888-77D8E37D4E41 Q38650815-855A82F1-5EAC-4A7E-86C6-48C8E8FB330E Q39051353-70DB786C-3686-4C13-B3B8-A9C13BD4367F Q41978574-6C201392-8896-4B86-9294-6558CA326492 Q44622061-8713725D-6D92-41FA-8D83-C589BBA30D90 Q46552875-B72A93F4-A4EF-499D-8C43-53E94F3A7CF3 Q50512175-0E94F1B8-1D16-4FB0-8E53-59E8297E15F9 Q51288024-946F6268-52C3-4AE4-87B8-89487FA7282C

P2860

Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

http://www.wikidata.org/entity/Q36666731

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

@ast

Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

@en

type

label

Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

@ast

Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

@en

prefLabel

Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

@ast

Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

@en

P1433

Q36666731-72266B1B-7484-4262-BEAC-30F29369EBDF

P1476

Q36666731-F7FDAFB5-5040-47D4-9E27-EBBB952FC351

P2093

Q36666731-0AD4DAC6-B315-418E-B239-57E516F26C27

Q36666731-38D43915-5D51-459E-B083-7EF6909E3CB5

Q36666731-5FA152EA-BF52-40E9-866B-4F7B45971582

Q36666731-5FB9C4E0-104D-4F1C-B630-BA9BBC237F3E

Q36666731-60A7E552-B374-4626-A92F-763A4D3D006C

Q36666731-98D9564A-7563-4AF7-8F75-62F77237FD00

P2860

Q36666731-401B76EA-CD37-4B9B-91A4-8BC429C3B0B9

Q36666731-48D3FCFA-589A-43EC-8E78-A307ACE78FDF

Q36666731-5BF0A110-DFA3-4DFC-B607-4ADFBDEB0A81

Q36666731-6B2B3B98-5858-4284-9A76-E486FE61F90F

Q36666731-822986E9-BF52-42C1-A4FA-3B651EE8EFAE

Q36666731-9B07C5C5-234A-496C-BE6B-63C0449BB656

Q36666731-B35375FD-8A55-4DED-9D86-6475A4984B0C

Q36666731-E9B9DB8B-3E8A-40C4-B9B1-3D3D405EBE74

P304

Q36666731-D2B04B7E-6AFF-4AD8-98FC-5CBC4E8EC209

P31

Q36666731-45FF602B-C1BB-49D4-B75E-CE043A83A40A

P356

Q36666731-47A04A9E-3A24-4204-A707-B69041792B7B

P433

Q36666731-3E6C41C6-8A5D-42AB-B1AC-234013069916

P478

Q36666731-CEC4108B-6F00-47C0-A91C-395E196FB4F2

P50

Q36666731-F9AC1D6B-AEB9-4DFF-B5A8-64B9AB6DA613

P577

Q36666731-B880FEDE-B691-4087-A46C-DC7610486731

P698

Q36666731-ED22BC16-3EF7-4D19-B383-E6909E70950F

P921

Q36666731-4813D084-73B9-49D9-9F4A-F54338DABDF0

P932

Q36666731-D236B5CB-A3A5-47CC-99D5-28AE0A25BD3C

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS)

@en

P2093

Adeera Levin

http://www.w3.org/2001/XMLSchema#string

Beverly Jung

http://www.w3.org/2001/XMLSchema#string

Ivana Dojcinovic

http://www.w3.org/2001/XMLSchema#string

Mercedeh Kiaii

http://www.w3.org/2001/XMLSchema#string

Ognjenka Djurdjev

http://www.w3.org/2001/XMLSchema#string

Steven Shalansky

http://www.w3.org/2001/XMLSchema#string

P2860

Sodium citrate 4% locking solution for central venous dialysis catheters--an effective, more cost-efficient alternative to heparin.

A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters.

A prospective, randomized, double-blind crossover study on the use of 5% citrate lock versus 10% citrate lock in permanent hemodialysis catheters.

Risks related to catheter locking solutions containing concentrated citrate.

Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients.

Establishment and maintenance of vascular access in incident hemodialysis patients: a prospective cost analysis.

Trisodium citrate 4%--an alternative to heparin capping of haemodialysis catheters.

Haemodialysis vascular access problems in Canada: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS II).

P304

369-374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.01760407

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer M MacRae

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18308996

http://www.w3.org/2001/XMLSchema#string

P921

P932

2390935

http://www.w3.org/2001/XMLSchema#string